National Heart, Lung, and Blood Institutes's Framingham Heart Study, Framingham, Mass., USA.
Circulation. 2010 Jan 26;121(3):357-65. doi: 10.1161/CIRCULATIONAHA.109.865352. Epub 2010 Jan 11.
Chronic kidney disease (CKD) is a risk factor for myocardial infarction (MI) and death. Our goal was to characterize the association between CKD severity and short-term outcomes and the use of in-hospital evidence-based therapies among patients with ST-segment elevation MI (STEMI) and non-ST-segment elevation MI (NSTEMI).
The study sample was drawn from the Acute Coronary Treatment and Intervention Outcomes Network registry, a nationwide sample of STEMI (n=19 029) and NSTEMI (n=30 462) patients. Estimated glomerular filtration rate was calculated with the Modification of Diet in Renal Disease equation in relation to use of immediate (first 24 hours) therapies and early (first 48 hours) cardiac catheterization as well as in-hospital major bleeding events and death. Overall, 30.5% and 42.9% of patients with STEMI and NSTEMI, respectively, had CKD. Regardless of MI type, patients with progressively more severe CKD had higher rates of death. For STEMI, the odds ratio for stage 3a, 3b, 4, and 5 CKD compared with patients with no CKD was 2.49, 3.72, 4.82, and 7.97, respectively (P(trend)<0.0001). For NSTEMI, the analogous odds ratios were 1.81, 2.41, 3.50, and 4.09 (P for trend <0.0001). In addition, patients with progressively more severe CKD were less likely to receive immediate evidence-based therapies including aspirin, beta-blockers, or clopidogrel, were less likely to undergo any reperfusion (STEMI) or revascularization (NSTEMI), and had higher rates of bleeding.
Reports over the past decade have highlighted the importance of CKD among patients with MI. Data from this contemporary cohort suggest that patients with CKD still receive fewer evidence-based therapies and have substantially higher mortality rates.
慢性肾脏病(CKD)是心肌梗死(MI)和死亡的危险因素。我们的目标是描述 CKD 严重程度与 ST 段抬高型心肌梗死(STEMI)和非 ST 段抬高型心肌梗死(NSTEMI)患者短期预后以及住院期间使用循证治疗之间的关系。
本研究样本来自急性冠状动脉治疗和干预结果网络注册中心,该中心是一个全国性的 STEMI(n=19029)和 NSTEMI(n=30462)患者的样本。使用肾脏病饮食改良公式计算肾小球滤过率,以评估即刻(前 24 小时)治疗和早期(前 48 小时)心脏导管检查以及住院期间大出血事件和死亡的使用情况。总的来说,STEMI 和 NSTEMI 患者分别有 30.5%和 42.9%患有 CKD。无论 MI 类型如何,CKD 程度逐渐加重的患者死亡率更高。对于 STEMI,与无 CKD 的患者相比,CKD 3a、3b、4 和 5 期的患者发生死亡的比值比分别为 2.49、3.72、4.82 和 7.97(P<0.0001)。对于 NSTEMI,相应的比值比分别为 1.81、2.41、3.50 和 4.09(P<0.0001)。此外,CKD 程度逐渐加重的患者更不可能接受即时的循证治疗,包括阿司匹林、β受体阻滞剂或氯吡格雷,不太可能进行任何再灌注(STEMI)或血运重建(NSTEMI),并且出血的发生率更高。
过去十年的报告强调了 CKD 在 MI 患者中的重要性。本当代队列研究的数据表明,CKD 患者仍接受较少的循证治疗,死亡率显著较高。